Carcinoma, Intraductal, Noninfiltrating clinical trials at UCSF
1 research study open to eligible people
Showing trials for
Pembrolizumab in High-risk Ductal Carcinoma in Situ (DCIS)
open to eligible females ages 18 years and up
This is a pilot study to investigate the change in the immune microenvironment of high risk ductal carcinoma in situ (DCIS) after short term exposure to pembrolizumab.
San Francisco, California
Our lead scientists for Carcinoma, Intraductal, Noninfiltrating research studies include Laura Esserman.